Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Aug 30.

Published in final edited form as: Int J Pharm. 2012 Aug 25;453(1):198–214. doi: 10.1016/j.ijpharm.2012.08.042

Table 1.

Summary of polymeric micelle-based formulations containing anticancer agents in clinical trials

Formulation	Drug	Polymer	Particle Size (nm)	Drug loading (%)	PK parameters (fold change over free drug)			Phase	Company
Formulation	Drug	Polymer	Particle Size (nm)	Drug loading (%)	t_1/2	AUC_blood	AUC_tumor	Phase	Company
Genexol-PM^{83, 84, 118, 119}	Paclitaxel	mPEG-PDLLA	< 50	16.7	0.62	0.74	1.74	III, IV	Samyang, Korea
NK105¹²⁰	Paclitaxel	PEG-P(Asp)	85	23.0	6.11^a, 3.71^b	86.11^a, 50.40^b	24.00^a, 24.06^b	II, III	Nanocarrier/Nippon Kayaku, Japan
SP1049C^{93, 94}	Doxorubicin	Pluronic L61, F127	30	8.2	1.38^c, 1.05^d	2.06^c, 1.20^d	1.69	III	Suprateck, Canada
DTXL-TNP⁹⁶	Docetaxel	PLA-PEG, PLA-PEG-ACUPA	100	10	n.a	n.a	n.a	I	BIND Biosciences
NC6004 ^{97, 121, 122}	Cisplatin	PEG-P(Glu)-Cisplatin	30	39.0	0.19	64.77	3.59	I, II	Nanocarrier, Japan
NK012 ^{99, 100}	SN-38	PEG-P(Glu)-SN38	20	20.0	16.41^e	14.09^e	9.53^e	II	Nippon Kayaku, Japan
NK911 ^{91, 103}	Doxorubicin	PEG-P(Asp)-Dox	40	N/A	2.62	28.88	3.46	II	Nippon Kayaku, Japan

^a

Dose: 50 mg/kg

^b

Dose: 100 mg/kg

^c

Data gathered in normal mice

^d

Data gathered in tumor-bearing mice

^e

Marketed in South Korea in 2007